Inotiv’s (NOTV) “Sell (E+)” Rating Reiterated at Weiss Ratings

Inotiv (NASDAQ:NOTV)‘s stock had its “sell (e+)” rating restated by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Inotiv Trading Up 9.4%

Shares of NASDAQ:NOTV opened at $1.52 on Wednesday. The business’s 50-day moving average is $1.65 and its 200 day moving average is $1.98. Inotiv has a 1 year low of $1.15 and a 1 year high of $6.48. The firm has a market capitalization of $52.21 million, a P/E ratio of -0.56 and a beta of 4.16. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.29 and a quick ratio of 0.96.

Inotiv (NASDAQ:NOTV) last announced its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The company had revenue of $130.70 million for the quarter, compared to analyst estimates of $127.05 million. Inotiv had a negative return on equity of 15.74% and a negative net margin of 15.63%. On average, research analysts predict that Inotiv will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of Inotiv

Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new stake in Inotiv during the 1st quarter valued at about $33,000. Corient Private Wealth LLC purchased a new stake in Inotiv during the 2nd quarter valued at about $44,000. McAdam LLC purchased a new stake in Inotiv during the 1st quarter valued at about $63,000. American Century Companies Inc. grew its stake in Inotiv by 16.4% during the 2nd quarter. American Century Companies Inc. now owns 41,933 shares of the company’s stock valued at $76,000 after purchasing an additional 5,894 shares during the last quarter. Finally, Kestra Private Wealth Services LLC purchased a new stake in Inotiv during the 1st quarter valued at about $94,000. Hedge funds and other institutional investors own 18.17% of the company’s stock.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.